These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 2635094)
1. Comparison of the safety and effectiveness of human and bovine long-acting insulins. Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094 [TBL] [Abstract][Full Text] [Related]
2. A comparison of human ultralente- and lente-based twice-daily injection regimens. Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130 [TBL] [Abstract][Full Text] [Related]
3. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM. Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498 [TBL] [Abstract][Full Text] [Related]
4. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521 [TBL] [Abstract][Full Text] [Related]
5. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Kudva YC; Basu A; Jenkins GD; Pons GM; Vogelsang DA; Rizza RA; Smith SA; Isley WL Endocr Pract; 2007; 13(3):244-50. PubMed ID: 17599855 [TBL] [Abstract][Full Text] [Related]
6. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. Burge MR; Waters DL; Holcombe JH; Schade DS J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507 [TBL] [Abstract][Full Text] [Related]
7. The subcutaneous absorption of human and bovine ultralente insulin formulations. Hildebrandt P; Berger A; Vølund A; Kühl C Diabet Med; 1985 Sep; 2(5):355-9. PubMed ID: 2951089 [TBL] [Abstract][Full Text] [Related]
8. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Taylor R; Davies R; Fox C; Sampson M; Weaver JU; Wood L Diabetes Care; 2000 Nov; 23(11):1612-8. PubMed ID: 11092282 [TBL] [Abstract][Full Text] [Related]
9. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. Francis AJ; Hanning I; Alberti KG Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523 [TBL] [Abstract][Full Text] [Related]
10. Human ultralente insulin. Holman RR; Steemson J; Darling P; Reeves WG; Turner RC Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
12. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man. Owens DR; Vora JP; Heding LG; Luzio S; Ryder RE; Atiea J; Hayes TM Diabet Med; 1986; 3(4):326-9. PubMed ID: 2949920 [TBL] [Abstract][Full Text] [Related]
13. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Kudva YC; Basu A; Jenkins GD; Pons GM; Quandt LL; Gebel JA; Vogelsang DA; Smith SA; Rizza RA; Isley WL Diabetes Care; 2005 Jan; 28(1):10-4. PubMed ID: 15616226 [TBL] [Abstract][Full Text] [Related]
14. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM. Rizza RA; O'Brien PC; Service FJ Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778 [TBL] [Abstract][Full Text] [Related]
15. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens. Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324 [TBL] [Abstract][Full Text] [Related]
16. A comparison of morning and bed-time ultralente administration when using multiple injections in adolescence. Smith CP; Dunger DB; Mitten S; Hewitt J; Spowart K; Grant DB; Savage MO Diabet Med; 1988; 5(4):352-5. PubMed ID: 2968885 [TBL] [Abstract][Full Text] [Related]
17. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins. Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669 [TBL] [Abstract][Full Text] [Related]
18. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Lindström T; Olsson PO; Arnqvist HJ Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253 [TBL] [Abstract][Full Text] [Related]
19. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Alemzadeh R; Berhe T; Wyatt DT Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Alemzadeh R; Ellis JN; Holzum MK; Parton EA; Wyatt DT Pediatrics; 2004 Jul; 114(1):e91-5. PubMed ID: 15231979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]